Supplemental Material, JCPT_Oct_2016_225_revised_CV_effect_revised_supplemental_materials_24_Jan_2018 - Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation

White, William B.; Kowey, Peter; Diva, Ulysses; Sostek, Mark; Tummala, Raj

doi:10.25384/SAGE.6371423.v2

JCPT_Oct_2016_225_revised_CV_effect_revised_supplemental_materials_24_Jan_2018.pdf (79.86 kB)

Supplemental Material, JCPT_Oct_2016_225_revised_CV_effect_revised_supplemental_materials_24_Jan_2018 - Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation

Version 2 2018-05-31, 17:05

Version 1 2018-05-28, 03:01

journal contribution

posted on 2018-03-04, 12:00 authored by William B. White, Peter Kowey, Ulysses Diva, Mark Sostek, Raj Tummala

Supplemental Material, JCPT_Oct_2016_225_revised_CV_effect_revised_supplemental_materials_24_Jan_2018 for Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation by William B. White, Peter Kowey, Ulysses Diva, Mark Sostek, and Raj Tummala in Journal of Cardiovascular Pharmacology and Therapeutics